OncoTyrol to Conduct Validation Studies on Protagen UniArray Technology

Jun 10, 2009

NEW YORK (GenomeWeb News) – Protagen said today that it has formed a collaboration with OncoTyrol to conduct validation studies on the firm's UniArray technology platform.

The study aims to determine the "most robust combination of putative prostate cancer markers and optimizing the diagnostic protein biochip to proceed to clinical trials," Protagen CEO Stefan Müllner said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

New Privacy Coalition

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

Less Sweat, More Diverse Microbiome

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

Oh, This Code

The Wall Street Journal examines billing codes used by uBiome.

PNAS Studies Look at Lung Cancer LncRNA, Hi-C Clustering, and More

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.

Featured White Papers

Optimized NGS Library Preparation with Acoustic Liquid Handling

Menu